Article

Factors influencing the level of circulating procoagulant microparticles in acute pulmonary embolism.

Cardiology Department, Saint-Antoine University and Medical School, Assistance Publique-Hôpitaux de Paris, université Pierre-et-Marie-Curie, 75571 Paris cedex 12, France.
Archives of cardiovascular diseases (Impact Factor: 0.66). 01/2010; 103(6-7):394-403. DOI: 10.1016/j.acvd.2010.06.005
Source: PubMed

ABSTRACT Flow cytometry has shown levels of platelet-derived microparticles (PMPs) and endothelial-derived microparticles (EMPs) to be elevated in deep-vein thrombosis. Cardiovascular risk factors can also contribute to hypercoagulability due to circulating procoagulant microparticles (CPMPs).
To investigate in a case-control study the respective contribution of pulmonary embolism and cardiovascular risk factors to the level of hypercoagulability due to CPMPs.
CPMP, PMP and EMP levels were measured in 45 consecutive patients (age 67.9 +/- 11.6 years; 66.7% men) admitted to an intensive care unit for acute pulmonary embolism (APE), 45 healthy control subjects with no history of venous thromboembolism or vascular risk factors (Controls(noCVRFs)), and 45 patients with cardiovascular risk factors (Controls(CVRFs)). APE was diagnosed by spiral computed tomography or scintigraphy. CPMP levels were assessed using a prothrombinase assay on platelet-depleted plasma (results expressed as nmol/L equivalent).
CPMP levels were higher in APE patients than in Controls(noCVRFs) (medians 4.7 vs 3.2 nmol/L, interquartile ranges [IQRs] 2.9-11.1 vs 2.3-4.6 nmol/L; p=0.02). Similar results were reported for PMPs (medians 2.2 vs 1.9 nmol/L, IQRs 1.7-5.8 vs 1.4-2.4 nmol/L; p=0.02), whereas EMP levels were not significantly different. However, CPMP procoagulant activity was not significantly different in APE patients and Controls(CVRFs).
CPMPs and PMPs were significantly elevated in APE patients vs Controls(noCVRFs), but this correlation was not significant when APE patients were compared with Controls(CVRFs). Our observations highlight the importance of adjusting for the presence of cardiovascular risk factors in conditions in which microparticle levels are raised.

0 Bookmarks
 · 
78 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Microparticles (MPs) are small vesicles between 100 and 500 nm, released from different cells including blood, endothelium, smooth muscle, and retina cells. MPs are produced during shedding process in response to some stressing and stimulating factors, as well as during apoptosis. The cellular machinery leading to MP shedding involves the loss of the plasma membrane asymmetry and phosphatidylserine externalization with an increase in cytosolic calcium concentrations. MPs not only transfer membrane proteins from the cells of their origin but also convey phospholipids and microRNA to the distant cells. Some of these macromolecules have neoangiogenetic properties (factor XII, tissue factor or mitogen-activated protein kinases) or participate in modulation of vascular senescence or remodeling (miRNAs). AREAS COVERED: The authors summarise recent knowledge about MP biology and pathophysiology. The mechanisms involved in MP release are discussed, and special emphasis is placed on clinical studies, which document their proangiogenic role in diabetic retinopathy and vascular aging. EXPERT OPINION: The pharmacological control of phospholipid moieties in the plasma membrane and the regulation of the MP shedding remains a challenge in the early stage of diabetic retinopathy and vascular aging.
    Expert opinion on therapeutic targets 05/2012; 16(7):677-88. · 3.72 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Microvesicles (MVs) are small (0.1-1 µm) membrane vesicles released from activated cells. The surface of MVs can be highly procoagulant due to the presence of the procoagulant protein tissue factor (TF) and of negatively charged phospholipids, such as phosphatidylserine. This review focuses on the potential utility of plasma MVs as a biomarker of venous thrombosis. The majority of studies have not found a clear relationship between venous thrombosis and phosphatidylserine-positive MVs or platelet MVs. Conversely, TF-positive MVs are increased in patients with venous thromboembolism. Studies with pancreatic cancer patients suggest that elevated levels of TF-positive MVs may be predictive of the development of venous thrombosis and patient survival. However, further studies are needed to determine if TF-positive MVs are a good biomarker for venous thrombosis in cancer and other diseases.
    Expert Review of Hematology 02/2013; 6(1):91-101. · 2.38 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abnormal thrombus formation and resolution underlie many vascular disorders, including venous thromboembolism (VTE), stroke, hypertension, and myocardial infarction. Conditions that account for both venous and arterial thrombosis such as the antiphospholipid antibody syndrome, hyperhomocysteinemia, malignancies, infections, and hormone treatment provide a pathophysiological link between arterial and venous thrombosis. Furthermore, recent trials have demonstrated that patients with VTE are at increased risk of arterial thrombosis. The scope of this chapter is to define the characteristics of venous thrombosis and VTE, the role of soluble factors, and to emphasize the role of the vascular wall and of circulating cells, thus creating a new view of thrombosis, beyond classic coagulation and fibrinolysis.
    Pulmonary circulation. 12/2013; 3(4).

Full-text (2 Sources)

View
23 Downloads
Available from
Jun 1, 2014